Baird Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $568
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $514 to $568.
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $514 to $568.
